Physician profile
David G Hicks
NPI 1386617157
$169,364.88
in general payments reported to CMS, 2019-2025
14 companies · $13K in 2025
The $13K reported for 2025 was more than what 94% of Anatomic Pathology providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $28K · 2021: $22K · 2022: $35K · 2023: $18K · 2024: $8,770 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $1,363 · Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $22,660.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,600.00 |
| Travel and Lodging | $1,363.43 |
| Food and Beverage | $532.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $77,656.48 | 2020-2025 | Enhertu |
| Genentech USA, INC. | $31,141.34 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $25,626.58 | 2019-2020 | |
| Ventana Medical Systems, INC. | $11,300.00 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $5,310.23 | 2019 | |
| Astrazeneca Uk Limited | $5,142.50 | 2020-2021 | |
| Daiichi Sankyo INC. | $4,528.87 | 2020-2025 | Enhertu |
| Siemens Medical Solutions USA, INC. | $3,919.00 | 2022 | |
| Agilent Technologies, INC. | $3,000.00 | 2023 | Pd-L1 Ihc 28-8 Pharmdx |
| F. Hoffmann-La Roche Ag | $700.00 | 2021 | |
| Eli Lilly and Company | $700.00 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $143.98 | 2025 | Xifaxan |
| Roche Diagnostics Corporation | $124.54 | 2023 | Pathway Anti-Her-2/Neu (4b5) Rabbit Monoclonal Primary Antibody |
| Novartis Pharmaceuticals Corporation | $71.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.